Incyte Corporation (INCY)

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4).

Famed investor Jim Cramer says investors shouldn't feel boxed out of the market as the benchmark S&P 500 index continued to print higher highs in the second half of 2025.  “Sometimes, it can feel like...

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Announces the Appointment of Dave Gardner as Executive Vice President and Chief Strategy Officer.

There has been some speculation on Seeking Alpha recently on several biotech/biopharma names that make logical buyout targets. Many firms are on their way to success as standalone entities and have go...

Incyte secures FDA nod for Opzeluras pediatric use in atopic dermatitis, marking its third U.S. approval and boosting sales momentum.

The U.S. Food and Drug Administration has approved Incyte's eczema treatment for children aged between 2 and 11 years, the company said on Thursday.

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Announces Additional FDA Approval of Opzelura® (Ruxolitinib) Cream in Children Ages 2-11 with Atopic Dermatitis.

Incyte's povorcitinib shows strong 24-week STOP-HS data in hidradenitis suppurativa, supporting 2025-2026 regulatory filings.

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #EADV25--Incyte Announces New 24-Week Phase 3 Data from the STOP-HS Clinical Trial Program of Povorcitinib in Hidradenitis Suppurativa at EADV 2025.

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte to Present New Data Highlighting Progress Across its Dermatology Pipeline at the EADV 2025 Congress.